Heart failure clinicsHumansPurinergic P2Y Receptor AntagonistsCytochrome P-450 CYP2C19ClopidogrelTicagrelor
Genetic Determinants of Response to P2Y12 Inhibitors and Clinical Implications.
Larisa H Cavallari, James C Coons
Published: 202610.1016/j.hfc.2025.09.002
Abstract
The CYP2C19 enzyme metabolizes clopidogrel, a prodrug, to its active form. Approximately 30% of individuals inherit a loss-of-function (LoF) polymorphism in the CYP2C19 gene, leading to reduced formation of the active clopidogrel metabolite. Reduced…
Preview only. Read the full abstract at the source